lasofoxifene has been researched along with Weight Gain in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brown, TA; Cameron, KO; Chen, HK; Chidsey-Frink, KL; Crawford, DT; Dasilva-Jardine, P; Grasser, WA; Jee, WS; Ke, HZ; Owen, TA; Paralkar, VM; Pirie, CM; Qi, H; Rosati, RL; Simmons, HA; Smock, SL; Thompson, DD | 1 |
| Aliaga, C; Cohen, LA; Moyer, JD; Pittman, B; Wang, CX; Yu, L | 1 |
2 other study(ies) available for lasofoxifene and Weight Gain
| Article | Year |
|---|---|
Effects of CP-336,156, a new, nonsteroidal estrogen agonist/antagonist, on bone, serum cholesterol, uterus and body composition in rat models.
Topics: Adipose Tissue; Aging; Animals; Apoptosis; Body Composition; Bone and Bones; Bone Marrow Cells; Cells, Cultured; Cholesterol; Estrogen Antagonists; Female; Gene Expression; Genes, p53; Organ Size; Osteocalcin; Ovariectomy; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptors, Estrogen; Tetrahydronaphthalenes; Uterus; Weight Gain | 1998 |
LAS, a novel selective estrogen receptor modulator with chemopreventive and therapeutic activity in the N-nitroso-N-methylurea-induced rat mammary tumor model.
Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents; Carcinogens; Estrogen Antagonists; Female; Mammary Neoplasms, Experimental; Methylnitrosourea; Pyrrolidines; Rats; Rats, Sprague-Dawley; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes; Weight Gain | 2001 |